Keliximab

Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]

Keliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (primate/human)
TargetCD4
Clinical data
Routes of
administration		intravenous
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NY (what is this?)  (verify)

References
  1. Kon, OM; Sihra, BS; Compton, CH; Leonard, TB; Kay, AB; Barnes, NC (1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet. 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587.
  2. WHO Drug Information


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.